Belgium-based iTeos Therapeutics SA, which is developing therapies targeting the tumour microenvironment, has appointed Gordon Freeman as chair of its scientific advisory board to advance the company’s preclinical and clinical assets. Dr Freeman is a researcher at the Dana-Farber Cancer Institute in Boston, US. Joining him on the board are William Hahn, chief research strategy officer at Dana-Farber, Ben Stanger, professor in cancer research at the University of Pennsylvania’s Perelman School of Medicine and Matthew Vander Heiden, associate director at the Massachusetts Institute of Technology’s Koch Institute for Integrative Cancer Research, US
iTeos announced the appointments on 10 September 2019
Copyright 2019 Evernow Publishing Ltd